Media coverage
23
Media coverage
Title Caribou Biosciences Announces FDA Clearance of IND Application for CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma Media name/outlet PipelineReview Country/Territory Spain Date 22/11/22 URL ct.moreover.com/?a=49317958823&p=1gw&v=1&x=p_SnJkPhWh1-RJDzlssWUw Persons Sundar Jagannath Title Caribou Biosciences Announces FDA Clearance of IND Application for CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma Media name/outlet Street Insider Country/Territory United States Date 21/11/22 URL ct.moreover.com/?a=49311175586&p=1gw&v=1&x=KMK0C0cX38DPigSar-opzg Persons Sundar Jagannath Title Caribou Bioscience (CRBU) Announces FDA Clearance of IND Application for CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma Media name/outlet Street Insider Country/Territory United States Date 21/11/22 URL ct.moreover.com/?a=49312180456&p=1gw&v=1&x=sCbd49VCl1cUJ1vHxWnxQw Persons Sundar Jagannath Title FDA Clearance of IND Application for CB 011, an Allogeneic Anti BCMA CAR T Cell Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma Media name/outlet Market News Publishing Country/Territory United States Date 21/11/22 URL ct.moreover.com/?a=49312017791&p=1gw&v=1&x=2rt0W_DUkXUVfja9B1aSVg Persons Sundar Jagannath Title Caribou Biosciences Announces FDA Clearance of IND Application for CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma Media name/outlet ADVFN UK Country/Territory United Kingdom Date 21/11/22 URL ct.moreover.com/?a=49310971238&p=1gw&v=1&x=NIlziOHjoCUpTBlkvhLEGg Persons Sundar Jagannath Title Caribou Biosciences Announces FDA Clearance of IND Application for CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma Media name/outlet Yahoo! Finance Country/Territory United States Date 21/11/22 URL ct.moreover.com/?a=49311009146&p=1gw&v=1&x=R66tiuMeNAmsv8z_ceI7YA Persons Sundar Jagannath Title Caribou Biosciences Announces FDA Clearance of IND Application for CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma Media name/outlet Market Newsdesk Country/Territory United States Date 21/11/22 URL ct.moreover.com/?a=49311273478&p=1gw&v=1&x=BSiuMsxaCy7OfLMNaQpfRA Persons Sundar Jagannath Title Caribou Biosciences Announces FDA Clearance of IND Application for CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma Media name/outlet PrimeNewswire (Top News) Country/Territory United States Date 21/11/22 URL ct.moreover.com/?a=49311167768&p=1gw&v=1&x=r31At9wtjySiDYWydfWeFA Persons Sundar Jagannath Title Caribou Biosciences Announces FDA Clearance of IND Application for CB-011, an Allogeneic Media name/outlet Bluefield Daily Telegraph Country/Territory United States Date 21/11/22 URL ct.moreover.com/?a=49311268406&p=1gw&v=1&x=pKv_94Z5vLptZ93vkz--Bg Persons Sundar Jagannath Title Caribou Biosciences Announces FDA Clearance of IND Application for CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma Media name/outlet BizWire Express Country/Territory India Date 21/11/22 URL ct.moreover.com/?a=49311151678&p=1gw&v=1&x=YeCNyzBpHfDM7ROkXDnlnw Persons Sundar Jagannath Title Caribou Biosciences Announces FDA Clearance of IND Application for CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma Media name/outlet 8 News Now Country/Territory United States Date 21/11/22 URL ct.moreover.com/?a=49311179602&p=1gw&v=1&x=fueMfbiFQmEkmYJinQKByQ Persons Sundar Jagannath Title Caribou Biosciences Announces FDA Clearance of IND Application for CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma Media name/outlet WJHL.com Country/Territory United States Date 21/11/22 URL ct.moreover.com/?a=49311202064&p=1gw&v=1&x=0q8dKbj9Ymj8nR0CqT7HSw Persons Sundar Jagannath Title Caribou Biosciences Announces FDA Clearance of IND Application for CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma Media name/outlet Fox 4 WDAF TV Country/Territory United States Date 21/11/22 URL ct.moreover.com/?a=49311208799&p=1gw&v=1&x=euksUofqvcmM8AucZ8RAvw Persons Sundar Jagannath Title Caribou Biosciences Announces FDA Clearance of IND Application for CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma Media name/outlet WRIC TV Country/Territory United States Date 21/11/22 URL ct.moreover.com/?a=49311225473&p=1gw&v=1&x=j80W6yW0YqklaFfOIthcrQ Persons Sundar Jagannath Title Caribou Biosciences Announces FDA Clearance of IND Application for CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma Media name/outlet NBC4 Columbus Country/Territory United States Date 21/11/22 URL ct.moreover.com/?a=49311238046&p=1gw&v=1&x=3Qyxy-6vhjldSvLCEM51Lw Persons Sundar Jagannath Title Caribou Biosciences Announces FDA Clearance of IND Application for CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma Media name/outlet News Channel 8 Country/Territory United States Date 21/11/22 URL ct.moreover.com/?a=49311257465&p=1gw&v=1&x=yoPLxAiBvQK2_mkbjNGQOQ Persons Sundar Jagannath Title Caribou Biosciences Announces FDA Clearance of IND Application for CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma Media name/outlet FOX5 San Diego Country/Territory United States Date 21/11/22 URL ct.moreover.com/?a=49311257994&p=1gw&v=1&x=MjrqPNGqB9or1YzjbLtGUQ Persons Sundar Jagannath Title Caribou Biosciences Announces FDA Clearance of IND Application for CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma Media name/outlet WGNO Country/Territory United States Date 21/11/22 URL ct.moreover.com/?a=49311269996&p=1gw&v=1&x=Oi6VE3hzhPRVYYlPx9Y8hg Persons Sundar Jagannath Title Caribou Biosciences Announces FDA Clearance of IND Application for CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma Media name/outlet FOX8 WGHP Country/Territory United States Date 21/11/22 URL ct.moreover.com/?a=49311277465&p=1gw&v=1&x=sGBv1ElvMISoHXAKbM6dGQ Persons Sundar Jagannath Title Caribou Biosciences Announces FDA Clearance of IND Application for CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma Media name/outlet WREG Country/Territory United States Date 21/11/22 URL ct.moreover.com/?a=49311279444&p=1gw&v=1&x=sjTVDi-rNiy6cph5jO8pEA Persons Sundar Jagannath Title Caribou Biosciences Announces FDA Clearance of IND Application for CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma Media name/outlet KXAN Country/Territory United States Date 21/11/22 URL ct.moreover.com/?a=49311314887&p=1gw&v=1&x=E7k_m82lcfgXnkVtjNqBVA Persons Sundar Jagannath Title Caribou Biosciences Announces FDA Clearance of IND Application for CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma Media name/outlet Everything Lubbock Country/Territory United States Date 21/11/22 URL ct.moreover.com/?a=49311342479&p=1gw&v=1&x=4y3k8LjPdSRZqcbnkOMkQA Persons Sundar Jagannath Title Caribou Biosciences Announces FDA Clearance of IND Application for CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma Media name/outlet WKRN Country/Territory United States Date 21/11/22 URL ct.moreover.com/?a=49311357086&p=1gw&v=1&x=YxdrFU7hZJ19YLRRhasO2g Persons Sundar Jagannath